Zacks Investment Research upgraded shares of Grifols, S.A. (NASDAQ:GRFS) from a hold rating to a buy rating in a research note published on Tuesday. Zacks Investment Research currently has $24.00 price objective on the biotechnology company’s stock.
According to Zacks, “Grifols, S.A., operates in the pharmaceutical-hospital sector engaged in the research, development and retailing of plasma derivates, products for intravenous therapy, clinical nutrition, diagnostic and hospital logistics systems. The Company operates its business through three divisions: Bioscience Division, Diagnostic Division and Hospital Division. The Bioscience division is engaged in the research, development, production and commercialization of plasma derivates. Diagnostic Division focuses on researching, developing, manufacturing and marketing diagnostics products for laboratory analysis, including products for Hospital Blood Banks and Transfusion Centers. Hospital Division provides non-biological products used in hospital pharmacies, surgery, nutritional support, fluid therapy and for other therapeutic uses. Grifols, S.A. is based in Barcelona, Spain. “
GRFS has been the topic of a number of other reports. Goldman Sachs Group, Inc. (The) downgraded shares of Grifols, from a buy rating to a neutral rating in a research note on Friday, June 30th. HSBC Holdings plc downgraded shares of Grifols, from a hold rating to a reduce rating in a research note on Friday, April 7th. BidaskClub cut shares of Grifols, from a buy rating to a hold rating in a research report on Friday, June 9th. Bank of America Corporation started coverage on shares of Grifols, in a research report on Thursday, April 6th. They set a buy rating for the company. Finally, J P Morgan Chase & Co raised shares of Grifols, from a neutral rating to an overweight rating in a research report on Thursday, March 30th. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company. The company has a consensus rating of Hold and a consensus price target of $24.00.
Shares of Grifols, (NASDAQ:GRFS) traded up 0.898% during mid-day trading on Tuesday, reaching $20.785. 281,346 shares of the company’s stock traded hands. Grifols, has a 12-month low of $14.27 and a 12-month high of $22.83. The firm has a market capitalization of $27.85 billion, a price-to-earnings ratio of 44.365 and a beta of 0.98. The stock has a 50-day moving average price of $21.42 and a 200 day moving average price of $18.78.
ILLEGAL ACTIVITY NOTICE: This piece was published by WKRB News and is owned by of WKRB News. If you are viewing this piece on another site, it was stolen and republished in violation of US & international copyright and trademark law. The original version of this piece can be read at https://www.wkrb13.com/markets/2285840/grifols-s-a-nasdaqgrfs-upgraded-by-zacks-investment-research-to-buy.html.
Hedge funds and other institutional investors have recently bought and sold shares of the company. Wells Fargo & Company MN boosted its position in Grifols, by 2.9% in the first quarter. Wells Fargo & Company MN now owns 171,871 shares of the biotechnology company’s stock worth $3,244,000 after buying an additional 4,842 shares in the last quarter. Wetherby Asset Management Inc. boosted its position in Grifols, by 14.0% in the first quarter. Wetherby Asset Management Inc. now owns 18,187 shares of the biotechnology company’s stock worth $343,000 after buying an additional 2,234 shares in the last quarter. Cardinal Capital Management boosted its position in Grifols, by 14.0% in the first quarter. Cardinal Capital Management now owns 40,479 shares of the biotechnology company’s stock worth $764,000 after buying an additional 4,975 shares in the last quarter. Huntington National Bank boosted its position in Grifols, by 1.2% in the first quarter. Huntington National Bank now owns 6,704 shares of the biotechnology company’s stock worth $127,000 after buying an additional 77 shares in the last quarter. Finally, CWM LLC boosted its position in Grifols, by 10.3% in the first quarter. CWM LLC now owns 82,287 shares of the biotechnology company’s stock worth $1,553,000 after buying an additional 7,668 shares in the last quarter. 22.12% of the stock is owned by institutional investors and hedge funds.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
This story was originally published by WKRB News (https://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://www.wkrb13.com/markets/2285840/grifols-s-a-nasdaqgrfs-upgraded-by-zacks-investment-research-to-buy.html
Receive News & Ratings for Grifols S.A. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Grifols S.A. and related companies with MarketBeat.com's FREE daily email newsletter.